“Preliminary results from the cohort study found no statistically significant difference in hospitalisation and 28-day case fatality between cases with the variant (VOC-201212/01) and wild-type comparator cases. There was also no significant difference in the likelihood of reinfection between variant cases and the comparator group.”
